CA
NZ
UK
AU
IND
US
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) reported a slightly deeper Q2 net loss of $2.27 million on revenue of $0.02 million.
Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares closed up 8% at $6.80 after the FDA pushed the Deramiocel PDUFA date for DMD to November 22, 2026, a three-month extension following the submission of a major BLA amendment containing long-term HOPE-3 extension data.
TuHURA Biosciences, Inc. (NASDAQ: HURA) accessed a further $650,000 from its $50 million revolving credit facility provided by Parkview Holdings, securing debt capital for operational needs.
Kairos Pharma, Ltd. (NYSE: KAPA) shares closed down 20% at $0.23 after announcing a 1-for-7 reverse stock split, a tactical move intended to meet exchange listing requirements.
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) secured orphan drug status from the European Commission for imsidolimab in generalized pustular psoriasis, a designation providing key regulatory and market incentives in the EU.
Biomea Fusion, Inc. (NASDAQ: BMEA) shares closed up 16% at $1.59 after the company completed target enrollment of 64 participants for the Phase 2 COVALENT-211 study of icovamenib in individuals with insulin-deficient type 2 diabetes.
REGENXBIO Inc. (NASDAQ: RGNX) shares faced pressure as the FDA implemented a clinical hold on RGX-121 for MPS II following the discovery of asymptomatic spinal MRI findings in five CAMPSIITE subjects, a setback that postpones the BLA resubmission.
Biomea Fusion, Inc. (NASDAQ: BMEA) successfully finalized enrollment of 64 subjects for its Phase 2 COVALENT-211 trial evaluating icovamenib in insulin-deficient type 2 diabetes.
● Zura Bio shares have jumped to $6.30, up 7.69%, on about 8.34 million shares traded, close to nine times the stock's average volume, marking real investor interest.
● Xenetic Biosciences shares have closed up 6.13% at $3.81, on about 102,790 shares changing hands, a small absolute figure but nearly five times the stock's recent norm.
Please wait processing your request...